Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.00 is 34% above its 3-year average of 0.00, around the middle of its 3-year range (0.00–0.01).
As of the fiscal period ended Tuesday, June 30, 2026. 36.68% below its 12-month average of 0.00.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00.
DEBT TO EQUITY RATIO
0.00
DEBT TO EQUITY RATIO AVG TTM
0.00
DEBT TO EQUITY RATIO AVG 3Y
0.00
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-36.68%
CURRENT VS 3Y AVG
+2.86%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.14
median of 511 covered companies
CURRENT VS SECTOR MEDIAN
-98.23%
vs the sector median at left
Bicara Therapeutics Inc. Common Stock
Market Cap
$1.10B
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
N/A
Market Cap
$1.09B
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.01
5Y Avg
0.02
Market Cap
$1.11B
Debt to Equity Ratio
0.90
TTM Avg
0.86
3Y Avg
0.72
5Y Avg
0.55
Market Cap
$1.08B
Debt to Equity Ratio
0.08
TTM Avg
0.07
3Y Avg
0.05
5Y Avg
0.04
Market Cap
$1.13B
Debt to Equity Ratio
19.79
TTM Avg
4.04
3Y Avg
3.72
5Y Avg
3.78
Market Cap
$1.03B
Debt to Equity Ratio
0.79
TTM Avg
0.91
3Y Avg
0.80
5Y Avg
0.56
Market Cap
$1.16B
Debt to Equity Ratio
0.83
TTM Avg
0.81
3Y Avg
0.86
5Y Avg
0.88
Market Cap
$1.17B
Debt to Equity Ratio
0.00
TTM Avg
0.05
3Y Avg
0.03
5Y Avg
0.02
Market Cap
$1.15B
Debt to Equity Ratio
0.04
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bicara Therapeutics Inc. Common Stock (BCAX) | $1.10B | 0.00 | 0.00 | 0.00 | N/A |
| IRadimed Corporation (IRMD)vs › | $1.09B | 0.00 | 0.00 | 0.01 | 0.02 |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.11B | 0.90 | 0.86 | 0.72 | 0.55 |
| Castle Biosciences, Inc. (CSTL)vs › | $1.08B | 0.08 | 0.07 | 0.05 | 0.04 |
| Harrow Health, Inc. (HROW)vs › | $1.13B | 19.79 | 4.04 | 3.72 | 3.78 |
| Teladoc Health, Inc. (TDOC)vs › | $1.03B | 0.79 | 0.91 | 0.80 | 0.56 |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.16B | 0.83 | 0.81 | 0.86 | 0.88 |
| Damora Therapeutics, Inc. (DMRA)vs › | $1.17B | 0.00 | 0.05 | 0.03 | 0.02 |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.15B | 0.04 | N/A | N/A | N/A |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.02B | 1.59 | 4.87 | 5.44 | 5.44 |
Debt/Equity
0.00
Current Ratio
11.59
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.00 |
| 2026-03-31 | 0.00 |
| 2025-12-31 | 0.00 |
| 2025-09-30 | 0.00 |
| 2025-06-30 | 0.01 |
| 2025-03-31 | 0.00 |
| 2024-12-31 | 0.00 |
| 2024-09-30 | 0.00 |
| 2024-06-30 | 0.00 |
| 2024-03-31 | 0.00 |
| 2023-12-31 | 0.00 |
| 2023-09-30 | 0.00 |
| 2023-06-30 | 0.00 |
| 2023-03-31 | 0.00 |
